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A broad range of studies suggest a two-way relationship between cancer and venous thromboembolism (VTE). Patients with cancer
have consistently been shown to be at elevated risk for VTE; this risk is partly driven by an intrinsic hypercoagulable state elicited by
the tumour itself. Conversely, thromboembolic events in patients without obvious risk factors are often the first clinical manifestation
of an undiagnosed malignancy. The relationship between VTE and cancer is further supported by a number of trials and meta-analyses
which, when taken together, strongly suggest that antithrombotic therapy can extend survival in patients with cancer by a mechanism
that extends beyond its effect in preventing VTE. Moreover, accumulating evidence from in vitro and in vivo studies has shown that
tumour growth, invasion, and metastasis are governed, in part, by elements of the coagulation system. On 22 May 2009, a group of
health-care providers based in the United Kingdom met in London, England, to examine recent advances in cancer-associated
thrombosis and its implications for UK clinical practice. As part of the discussion, attendees evaluated evidence for and against an
effect of antithrombotic therapy on survival in cancer. This paper includes a summary of the data presented at the meeting and
explores potential mechanisms by which antithrombotic agents might exert antitumour effects. The summary is followed by a
consensus statement developed by the group.
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As reviewed elsewhere in this supplement, patients with cancer are
at increased risk of venous thromboembolism (VTE), not only as a
result of extrinsic factors (e.g., immobility, cancer treatment,
surgery) but also as a result of an intrinsic hypercoagulable state
caused by the tumour itself. Conversely, it has been shown that
VTE often heralds an undiagnosed malignancy. Taken together,
these data suggest that there is a two-way relationship between
cancer and VTE. This link has been clearly established by
numerous epidemiological studies; moreover, it has been shown
that antithrombotic therapy – particularly with heparins – may
extend survival in patients with cancer. Additional in vitro and
in vivo data provide preliminary evidence that elements of the
coagulation system itself are critical determinants of cancer
growth, invasion, and metastasis. These data suggest that, beyond
the intuitively obvious benefit of preventing VTE in patients with
cancer, antithrombotic therapies may have a direct antitumour
effect, thus prolonging life and perhaps suppressing metastasis.
On 22 May 2009, a group of health-care professionals based in
the United Kingdom met in London, England, to examine recent
advances in cancer-associated thrombosis and its implications for
UK clinical practice. As part of the discussion, attendees reviewed
clinical and experimental evidence suggesting an effect of anti-
thrombotic therapy on survival in cancer patients. This paper
includes a summary of the data presented at the meeting and
explores potential mechanisms by which antithrombotic agents
might exert antitumour effects. The summary is followed by a
consensus statement developed by the group.
EFFECTS OF ANTITHROMBOTIC THERAPY ON
SURVIVAL IN CANCER
A number of clinical trials, of varying quality, have assessed the
impact of antithrombotic therapy on cancer outcome. When
considered together, the results of these studies suggest that
antithrombotic agents – including warfarin, unfractionated
heparin (UFH), and low-molecular-weight heparins (LMWH) –
may prolong the survival of patients with malignant diseases.
Indirect evidence suggests that warfarin may have an impact on
cancer occurrence. A prospective study randomised patients with
VTE to either 6 weeks or 6 months of oral anticoagulation; patients
were questioned yearly thereafter about any newly diagnosed
cancer (Schulman and Lindmarker, 2000). An analysis, conducted
after a mean follow-up of 8.1 years, found that cancer was
diagnosed in 15.8% of patients who were treated for 6 weeks with
oral anticoagulants, compared with 10.3% of those treated for
6 months (OR 1.6; 95% CI 1.1–2.4) (Schulman and Lindmarker,
2000). Notably, the difference between the 6-week and 6-month
groups was driven primarily by the occurrence of new urogenital
cancers (most commonly prostate cancer), which occurred in 6.7%
of the 6-week group and in 2.8% of the 6-month group (Schulman
and Lindmarker, 2000). More recently, Tagalakis et al (2007)
examined the effect of warfarin in patients with urogenital cancer.
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Canada (Tagalakis et al, 2007). Four years of warfarin use in the
5-year period immediately preceding the index date was associated
with a rate ratio of 0.80; there was a trend towards a decreasing
rate ratio for prostate cancer with increasing duration of warfarin
use through 5 years (Tagalakis et al, 2007). Although interesting,
neither of these studies indicate whether warfarin therapy prevents
or merely delays the onset of cancer, nor whether it affects overall
mortality.
An early trial of warfarin – the VA Cooperative Study #75 –
directly examined the effect of warfarin on survival in patients with
cancer. In this study, 431 patients with malignancies were
randomised to either warfarin or placebo in addition to their
standard cancer treatment (Zacharski et al, 1984). No differences
in survival were observed between treatment groups for patients
with advanced non-small-cell lung, colorectal, prostatic, or head
and neck cancer (Zacharski et al, 1984). A trend towards improved
survival was seen in patients with non-small-cell lung cancer after
surgical resection or potentially curative radiation therapy.
Notably, warfarin was associated with a significant improvement
in survival (P¼0.018) in a small subset of 50 patients with small-
cell lung cancer (SCLC); these patients also had a significantly
increased time to disease progression compared with controls
(Zacharski et al, 1984).
A similar three-arm trial by CALGB (Chahinian et al, 1989)
randomised 328 patients with extensive SCLC to a standard
chemotherapy regimen (MACC), to the regimen with concurrent
warfarin, or to an alternating chemotherapy regimen. The overall
response rate was significantly higher in the warfarin arm than in
the others (P¼0.012), but although there was also a trend towards
improved survival, this did not reach statistical significance
(Chahinian et al, 1989).
Another trial, published by Maurer et al (1997), also attempted
to confirm the results of the VA Cooperative Study in limited-stage
SCLC patients. As in the previous study, patients were randomised
to receive warfarin or no warfarin, in addition to cancer
chemotherapy and radiation therapy. There were no significant
differences between the warfarin and no-warfarin groups in terms
of response rates, survival, failure-free survival, disease-free
survival, or patterns of relapse (Maurer et al, 1997). However,
the trial was confounded by a protocol amendment after accrual of
179 patients because of pulmonary toxicity with a reduction of the
chemotherapy regimen from eight cycles to five cycles (Maurer
et al, 1997).
Only one study has reported on the effects of UFH on survival.
In this study, 277 patients with SCLC were randomised to either
receive or not receive dose-adjusted subcutaneous UFH injections
for 5 weeks, in addition to chemotherapy (Lebeau et al, 1994). In
this study, heparin was associated with improved complete
response rates (37 vs 23%; P¼0.004); improved median survival
(317 days vs 261 days; P¼0.01); and better survival rates at 1 year
(40 vs 30%), 2 years (11 vs 9%), and 3 years (9 vs 6%) (Lebeau et al,
1994). A subgroup analysis suggested that the effect on survival
was only in patients with limited disease.
The effect of LMWH on survival has been more extensively
studied. An early analysis of two studies, conducted by Green et al
(1992), provided initial evidence that mortality was reduced in
patients treated with LMWH, compared with those who received
UFH. A meta-analysis of trials comparing UFH with LMWH,
published in 1996, provided additional evidence that LMWH is
associated with reduced mortality in patients with cancer (Siragusa
et al, 1996). As expected, both UFH and LMWH were effective in
preventing recurrent VTE. An analysis of four studies in patients
with cancer found that mortality rates during the 16- to 90-day
follow-up period of oral anticoagulant therapy were substantially
lower among patients assigned to the LMWH group (12%)
compared with the UFH group (26%) (RR 0.33; 95% CI 0.1–0.8;
P¼0.01) (Siragusa et al, 1996). The mortality rate in patients
without cancer was low and was not significantly different between
the two groups. Notably, significant reduction in mortality in
cancer patients who received LMWH was not observed during the
initial 15 days of treatment. Instead, the majority of deaths
occurred after ceasing LMWH or UFH, which suggests that the
effect of LMWH in preventing mortality was not because of its
antithrombotic effect (Siragusa et al, 1996). A second meta-
analysis (1999) also found a striking 57% reduction in mortality
with LMWHs compared with UFH in the small subgroup of
patients with cancer (Gould et al, 1999).
The effect of LMWH on survival in cancer was tested directly in
the Fragmin Advanced Malignancy Outcome Study (FAMOUS)
(Kakkar et al, 2004). In this study, 385 patients with advanced
malignancies (histologically confirmed, advanced stage III or IV
disease of the breast, lung, gastrointestinal tract, pancreas, liver,
genitourinary tract, ovary, or uterus) were randomly assigned to
receive either dalteparin (5000IU administered once daily) or
placebo (Kakkar et al, 2004). There were no restrictions on
concomitant use of chemotherapy or radiotherapy. Patients were
followed for 1 year for the primary end point of mortality;
secondary outcomes included objectively confirmed VTE and
bleeding (Kakkar et al, 2004). Rates of symptomatic VTE were low
in both the dalteparin (2.4%) and placebo (3.3%) groups; bleeding
was seen in 4.7% of dalteparin patients and in 2.7% of placebo
patients (Kakkar et al, 2004).
At 1 year after randomisation, survival estimates in the
dalteparin and placebo groups were 46 and 41%, respectively
(P¼0.19; Figure 1A). At 2 years, survival rates were 27 and 18%
for the dalteparin and placebo groups, respectively, and at 3 years
the rates were 21 and 12%, respectively (Kakkar et al, 2004). Post
hoc analysis of patients with a better prognosis who survived more
than 17 months showed a survival advantage for the dalteparin
group (Kakkar et al, 2004). At 2 and 3 years after randomisation,
survival in the dalteparin and placebo groups was 78 vs 55% and
60 vs 36%, respectively (P¼0.03; Figure 1B). Median survival in
the dalteparin group was 43.5 months, compared with 24.3 months
in the placebo group (Kakkar et al, 2004).
The effect of LMWH on survival in patients with SCLC was
evaluated directly in a study conducted by Altinbas et al (2004). In
this small study, 84 patients were randomised to receive
combination chemotherapy with or without dalteparin (5000IU
once daily during the 18 weeks of combination chemotherapy)
(Altinbas et al, 2004). Tumour response rates were substantially
higher among patients who received LMWH (69.2%) compared
with those who did not (42.5%), but the difference between the two
groups was not statistically significant (P¼0.07). Median progres-
sion-free survival was 10.0 and 6.0 months in the LMWH and no-
LMWH groups, respectively (P¼0.01), with similar improvements
in survival with LMWH observed in patients with both limited and
extensive disease stages. Overall, the hazard of death was reduced
by 44% among patients who received LMWH (P¼0.012) (Altinbas
et al, 2004).
A second recent trial prospectively examined the effect of
LMWH on survival in patients with advanced malignancies (Klerk
et al, 2005). Patients with metastatic or locally advanced solid
tumours who could not be treated curatively were randomly
assigned to receive a 6-week course of weight-adjusted nadroparin
(administered twice daily during the initial 14 days of treatment
and once daily thereafter for an additional 4 weeks) or placebo
(Klerk et al, 2005); concomitant chemotherapy or radiotherapy
was permitted. The primary end point was all-cause mortality, the
secondary end point was major and clinically relevant non-major
bleeding (Klerk et al, 2005).
At 6 months, survival was 61% among patients randomly
allocated to nadroparin, compared with 56% in the placebo group
(Klerk et al, 2005). At 12 and 24 months, the corresponding values
were 39 vs 27% and 21 vs 11% (Figure 2A) (Klerk et al, 2005).
Among all patients, median survival was significantly longer in the
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(6.6 months; hazard ratio 0.75; 95% CI 0.59–0.96; P¼0.021).
After adjustment for life expectancy, WHO performance status,
concomitant treatment, and type and histology of cancer, the
relationship between nadroparin and improved survival remained
statistically significant (hazard ratio, 0.76; 95% CI 0.58–0.99)
(Klerk et al, 2005).
Consistent with the results seen in the FAMOUS trial, the effect
of nadroparin on survival was most apparent among patients with
a better prognosis at enrollment (defined as an estimated life
expectancy of X6 months; Figure 2B) (Klerk et al, 2005). In this
group, the hazard ratio was 0.64 (95% CI 0.45–0.90; P¼0.010),
compared with 0.88 (95% CI 0.62–1.25) in those with a life
expectancy of o6 months. Median survival in the good-prognosis
group was 15.4 months and 9.4 months for the nadroparin and
placebo groups, respectively. There was no significant difference in
the rate of major bleeding between the nadroparin group (five
events) and the placebo group (one event; P¼0.12) (Klerk et al,
2005).
In contrast to these data, a trial conducted by Sideras et al
(2006) found that LMWH did not influence survival times in
patients with advanced cancer. This small study, including 141
participants, initially randomised patients with advanced cancer
to treatment with LMWH or saline. Because of low accrual, the
placebo injection arm was eliminated and the study became open
label, with patients receiving either LMWH plus standard clinical
care or standard clinical care alone (Sideras et al, 2006). Median
survival was 10.5 months in the combined standard care and
placebo groups and 7.3 months in the combined LMWH arms.
When the two arms from the initial, blinded phase of the study
were examined, the median survival times were 6.2 months in the
LMWH arm and 10.3 months in the placebo arm (Sideras et al,
2006).
A recent systematic meta-analysis of randomised trials suggests
that LMWH, on balance, improves overall survival in cancer
patients, including those with advanced disease (Lazo-Langner
et al, 2007). This meta-analysis included four studies, enrolling 898
patients with solid tumours who were randomly allocated to either
LMWH or placebo (Lazo-Langner et al, 2007). Three studies used
dalteparin (5000IU daily) for 18 weeks, 1 year, or 2 years; one used
6 weeks of weight-adjusted nadroparin, with a high dose during
the first 2 weeks (Lazo-Langner et al, 2007).
At 1 year, the pooled results of the studies showed a 30%
reduction in the hazard of death in favour of the LMWH group
(P¼0.05; Figure 3); for patients with less advanced disease, there
was a 25% reduction in the hazard of death (P¼0.04) (p 731). At
2 years, LMWH reduced mortality in all patients by 43% (P¼0.03),
and by 41% (P¼0.004) in patients with advanced disease. LMWH
conferred a statistically significant improvement in survival at
both 12 and 24 months (Lazo-Langner et al, 2007).
In summary, there is accumulating evidence that anticoagulant
therapy may increase survival in some patients with cancer.
Further studies are currently ongoing to confirm the effects of
anticoagulant therapy in a range of tumour types. The largest of
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Figure 1 (A) Survival curves for the intent-to-treat population enrolled in the FAMOUS trial; (B) survival curves for the subgroup of patients with better
prognosis who survived beyond 17 months after randomisation (Kakkar et al, 2004).
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In patients with lung Cancer) trial (Wales Cancer Trials Unit,
2009), which is currently enrolling patients with pathologically
confirmed lung cancer (of all histological types and all stages) who
will be randomly allocated to standard care or standard care plus
6 months of treatment with dalteparin. This trial aims to recruit 2200
patients and is powered to detect a 5% increase in 1-year survival.
The GASTRANOX Study (ClinicalTrials.gov, 2009) is enrolling up to
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Figure 2 (A) Probability of survival in all patients with advanced solid malignancy according to assignment to nadroparin or placebo; (B) probability of
survival in patients with advanced solid malignancy with a life expectancy of X6 months at enrollment, according to assignment to nadroparin or placebo
(Klerk et al, 2005).
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Figure 3 One- and 2-year mortality in cancer patients randomised to LMWH vs placebo/no intervention (Lazo-Langner et al, 2007).
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allocated to LMWH enoxaparin (1mgkg
 1day
 1) for 6 months with
chemotherapy or chemotherapy alone. The primary end point of the
trial is the composite of all-cause mortality and symptomatic VTE.
POTENTIAL MECHANISMS FOR THE EFFECT OF
ANTITHROMBOTIC THERAPY ON SURVIVAL IN
CANCER
The results of individual clinical trials and meta-analyses, on
balance, seem to indicate that antithrombotic therapy – and
particularly LMWH – has an effect on survival in patients with
cancer. Although this observation is relatively consistent across
studies, it is difficult to understand how a short course of LMWH
can provide a substantial survival advantage in patients with
cancer. Recent data suggest that antithrombotic therapy may have
a direct tumour biology-modifying effect.
A large number of circulating proteins, usually in inactive form,
are involved in the haemostatic cascade. The activation of these
factors culminates in the formation of the fibrin network of the
clot and is countered by the fibrinolytic cascade, which, when
activated, results in thrombus degradation. Cancer itself seems to
elicit a systemic hypercoagulable state. Production of a wide range
of procoagulant molecules, including tissue factor (TF) and cancer
procoagulant (CP), a cysteine protease growth factor, has been
demonstrated in patients with cancer, as well as increased levels of
procoagulant markers, including TF, activated factor VII (FVIIa),
prothrombin-activation peptide, and thrombin–antithrombin
complexes (a comprehensive review can be found in Petralia
et al (2005). Recent evidence suggests that the production of
procoagulant molecules in patients with cancer is more than a
mere side effect of cancer growth; instead, data suggest that these
factors have an integral role in malignancy through eliciting
tumour growth, invasion, metastasis, and angiogenesis. These data
provide a potential link between the use of anticoagulant therapies
and improved survival in patients with cancer.
Tissue factor, a cell-surface bound, transmembrane glycoprotein,
has been shown to be expressed on a variety of tumours derived from
the epithelium. Tissue factor interacts with FVIIa to form the TF–VIIa
complex – the primary activator of coagulation (Petralia et al, 2005).
This complex seems to have a role in cell adhesion and migration
through the recruitment of actin-binding protein 280 (filamin A), an
intracellular protein implicated in cell motility (Ott et al, 1998).
In vitro, immobilised ligands for TF specifically support cell adhesion,
spreading, and intracellular signalling, suggesting that the interaction
between the cytoplasmic domain and filamin A may support tumour
cell metastasis and vascular remodelling. Cancer procoagulant is also
expressed by a wide range of tumours. It has the ability to initiate
the haemostatic cascade directly by activating FX independently of
the TF–VIIa complex.
Tissue factor expression has been shown to dramatically change
tumour behaviour. In animal models, overexpression of TF in
cancer cells has been shown to significantly upregulate over 40
genes and downregulate nearly 230 genes involved in transcrip-
tion, translation, intercellular signalling, cell growth, and apoptosis
(Wang et al, 2004). Tissue factor expression correlates with
histological grade and heralds the transformation from benign to
malignant phenotype (Kakkar et al, 1995). Overexpression of TF in
experimental models of pancreatic adenocarcinoma enhances
in vitro invasion and primary tumour growth (Kakkar et al,
1999). Similarly, overexpression in a mouse sarcoma model resulted
in increased levels of proangiogenic vascular endothelial growth
factor (VEGF) and suppression of thrombospondin, an antiangio-
genic regulatory protein (Zhang et al, 1994). In human breast
cancer, TF expression has been shown to correlate with an invasive
phenotype and initiation of angiogenesis (Contrino et al, 1996).
Tissue factor expression in hepatocellular cancer is strongly
associated with VEGF-induced angiogenesis and venous invasion
(Poon et al, 2003), potentially mediated by an interaction with
integrin aIIIbI. Moreover, TF-expressing cells seem to be protected
from apoptosis induced by serum deprivation and loss of adhesion,
suggesting a potential mechanism by which TF may promote
metastasis (Versteeg et al, 2004).
These data are consistent with the known role of TF in
enhancing wound healing, in which it indirectly induces prolifera-
tion of human vascular endothelial cells and promotes endothelial
cell alignment through the production of thrombin (Carney et al,
1992; Haralabopoulos et al, 1997). Protease-activated receptor-1
(PAR-1) is a receptor for thrombin that is overexpressed in a range
of tumour cell lines, particularly metastatic cell lines. Thrombin–
PAR signalling has been shown to upregulate expression of TF and
urokinase plasminogen in prostate cancer, increase invasiveness of
breast and pancreatic cell lines, and enhance procoagulant activity
in colon cancer (Petralia et al, 2005).
Together, it is clear that there is a role for elements of
the haemostatic system in cancer progression that extends
beyond their role in fibrin generation. These data also suggest
mechanisms through which antithrombotic treatments, such as
LMWH, may have a direct impact on tumour phenotype, as well
as influence survival in patients with cancer, beyond their effect
in suppressing VTE.
CONSENSUS STATEMENT
Although the association between cancer and an increased risk of
thromboembolism is well understood, the evidence that anti-
coagulant therapy may improve survival in cancer patients has
been slow to accumulate. The results of studies have been quite
heterogeneous in both the patient population and the anti-
coagulant used. Many of the studies have also been underpowered
to show clinically significant improvements in survival. However,
it does seem that there is a beneficial effect even from quite short
courses of treatment, and it seems that heparins may be more
effective than coumarins, and that this effect may be more marked
in patients with better prognosis. The beneficial effects do not
seem to come at the expense of a significant risk of adverse effects,
haemorrhage in particular.
Together, these findings suggest that, although there may be a
short-term benefit in preventing thromboembolism in a group of
patients at increased risk, there may also be a longer-term effect on
the cancer itself. This hypothesis is supported by a number of
in vitro and animal studies indicating a link between key factors in
the coagulation cascade and tumour growth and metastasis.
In addition to continuing investigation of the detailed mecha-
nisms of the complex interactions between growing tumour cells
and the coagulation cascade, there are a number of important
questions to be answered before routine anticoagulant therapy is
integrated into cancer therapy:
  How large and how consistent is any survival benefit?
  Which patients (tumour type, stage, prognostic category) are
most likely to benefit from therapy?
  Which anticoagulant is most effective?
  What duration of treatment is needed?
  How large is the risk of significant adverse effects?
We would therefore urge participation in the ongoing clinical
trials and in planning of future studies to make the most of this
fascinating and potentially important area of cancer treatment.
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